GlassScriptPhysician profile
Sharon W Greenberg
NPI 1033432968
$5,165.61
in general payments reported to CMS, 2019-2025
41 companies · $1,108 in 2025
The $1,108 reported for 2025 was more than what 85% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,170 · 2022: $932 · 2023: $961 · 2024: $995 · 2025: $1,108.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,063.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,063.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,052.76 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $556.02 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $539.89 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Amgen INC. | $372.66 | 2021-2025 | Otezla, Repatha, Otezla |
| Janssen Pharmaceuticals, INC | $310.08 | 2021-2024 | Spravato, Xarelto |
| Lilly USA, LLC | $289.08 | 2021-2025 | Mounjaro, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $242.38 | 2021-2025 | Jardiance, Spiriva Respimat, Synjardy |
| Merck Sharp & Dohme LLC | $128.70 | 2021-2023 | Verquvo, Belsomra, Steglatro |
| Daiichi Sankyo INC. | $124.60 | 2021-2024 | Injectafer |
| Glaxosmithkline, LLC. | $113.28 | 2021-2024 | Shingrix, Arexvy, Trelegy Ellipta |
| Bayer Healthcare Pharmaceuticals INC. | $99.87 | 2022-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $97.58 | 2021-2022 | |
| Shield Therapeutics INC | $88.55 | 2023-2025 | Accrufer |
| Exact Sciences Corporation | $86.54 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $81.95 | 2025 | Caplyta |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $72.84 | 2022-2025 | Freestyle Libre 3 |
| Kowa Pharmaceuticals America, INC. | $72.33 | 2022-2023 | Seglentis |
| Dexcom, INC. | $69.58 | 2021-2025 | Dexcom G6 Transmitter |
| Astellas Pharma US INC | $68.73 | 2024-2025 | Veozah |
| Amarin Pharma, INC. | $66.67 | 2021 | |
| Idorsia Pharmaceuticals US INC | $59.37 | 2022-2023 | Quviviq |
| Biohaven Pharmaceuticals, INC. | $53.18 | 2021 | |
| Novartis Pharmaceuticals Corporation | $50.61 | 2024-2025 | |
| Pfizer INC. | $49.18 | 2023-2024 | |
| Phathom Pharmaceuticals, INC. | $46.45 | 2024-2025 | Voquezna |
| Boston Scientific Corporation | $38.15 | 2021-2024 | Watchman Flx |
| Amneal Pharmaceuticals LLC | $37.45 | 2022-2025 | Unithroid |
| Medtronic, INC. | $31.47 | 2025 | Minimed 780g |
| Teva Pharmaceuticals USA, INC. | $28.18 | 2025 | Austedo Xr |
| Sanofi-Aventis U.S. LLC | $23.47 | 2021 | |
| Xeris Pharmaceuticals, INC. | $23.18 | 2025 | Gvoke Hypopen |
| Alvogen INC | $22.67 | 2025 | Teriparatide |
| Actelion Pharmaceuticals US, INC. | $22.15 | 2023 | Opsumit, Uptravi |
| Otsuka America Pharmaceutical, INC. | $21.60 | 2024 | Rexulti |
| Indivior INC. | $20.34 | 2025 | Sublocade |
| Biohaven Pharmaceutical Holding Company LTD. | $18.67 | 2022 | |
| Orexo US, INC. | $18.11 | 2025 | |
| Almatica Pharma LLC | $17.55 | 2021 | |
| Lundbeck LLC | $17.32 | 2023 | Vyepti |
| Ironwood Pharmaceuticals, INC | $16.69 | 2021 | |
| Eisai INC. | $15.73 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sharon Greenberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.